Safety profile of H2-receptor antagonists: current status of famotidine.
An assessment of the adverse reactions associated with H2-receptor blockers is presented, with particular emphasis towards famotidine. Post-marketing studies on the H2-receptor blockers have shown that they have a low incidence of adverse reactions (1-2% of patients) and are very effective in the treatment of peptic ulcers. The most common adverse reactions are gastro-intestinal, although central nervous system, cardiovascular, haematological, endocrine and hepatic disturbances may occur. Drug interactions and the considerable amount of post-marketing surveillance data, spanning over a decade of use, are also assessed.
Levine
J B
JB
Division of Gastroenterology, University of Connecticut Health Center, Farmington.
D000897:Anti-Ulcer Agents / Q000009:adverse effects*; D002927:Cimetidine / Q000009:adverse effects; D004347:Drug Interactions; D015738:Famotidine; D006635:Histamine H2 Antagonists / Q000009:adverse effects; D006801:Humans; D011899:Ranitidine / Q000009:adverse effects; D013844:Thiazoles / Q000009:adverse effects*
D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D013844:Thiazoles; D015738:Famotidine; D002927:Cimetidine; D011899:Ranitidine